Disease-by-disease, gene-by-gene drug development remains prohibitively expensive for the 6,000+ ultra-rare and #rarediseases. #tRNA could radically transform this paradigm to scale and accelerate new #geneticmedicines. Lean more in this Technology Networks feature Q&A with our CEO

🧬 RNA Therapeutics, from Concept to Clinic Our VP, Discovery Platform, Caroline Köhrer, will be speaking at #RNATx2024 next week and sharing how Alltrna is developing #tRNA medicines for #StopCodonDisease. Register to attend virtually: umassmed.edu/RNATx/

Inspiring words from our CEO Michelle Werner, who shares her personal and professional drive for accelerating and scaling the development of new genetic medicines for #rarediseases in this interview with Patrick Short on The Genetics Podcast. Michelle also discusses how she’s

As part of #PrideMonth2024, we hosted a book club and read “The Autobiography of a Transgender Scientist” by Dr. Ben Barres. Dr. Barres’s legacy is two-fold: making breakthrough discoveries for neuroscience by elucidating the role of glial cells and his groundbreaking advocacy

Companies pioneering original science are essential to scaling and accelerating meaningful new medicines for patients -- especially those with #rarediseases. We are proud to be one with the first #tRNA platform company to decipher tRNA biology and pioneer new #geneticmedicines to

What will it take to advance the first tRNA medicines into the clinic? 🎙️ Tune in to this podcast with #RNALeaders to hear our CEO Michelle Werner share her thoughts about the next steps to support the development of this unique therapeutic modality, which has the potential to

Please join us in welcoming Chris Schade, Lynne Parshall, Robert Plenge, and Nancy Simonian, who join Lovisa Afzelius and Michelle Werner on Alltrna’s Board of Directors. Their expertise will help guide us as we advance our first #tRNA medicines to the clinic for #StopCodonDisease

Our CEO Michelle Werner will be speaking tomorrow to Congressional leaders about the vital importance of the rare pediatric disease priority review voucher (PRV) program. The reauthorization of the #PRV program before the September 30th deadline would continue the crucial

Our CEO Michelle Werner chats with Tides Global about her journey leading up to being CEO at Alltrna and how her personal experiences influenced her career to advance novel therapeutics. Read more at Informa Plc: lifesciences.connectmeinforma.com/community/tide… #rarediseases #geneticmedicines #tRNA

🏖️ Relaxed, rejuvenated, and returning with a renewed focus on our mission. The Alltrna team enjoyed a synchronous #summerbreak at the beginning of July. It was a wonderful opportunity to reconnect with family, friends, and the world around us. Here's a peek at what we got up to.

Why does Alltrna need #machinelearning to unlock #tRNA biology? tRNAs are programmable molecules with a diverse biology of sequences and modifications that are key to their structure, function, and stability. There’s the potential for approximately 10^34 tRNA sequences and more

Of the ~300 million people around the world with a genetic disease, an estimated 10% have a nonsense mutation that causes a premature stop codon. Our CEO Michelle Werner shares with Daniel S. Levine how Alltrna is developing tRNA therapeutics as universal medicines for these diseases

We are excited to share that Alltrna has been selected as a finalist for the Biotech Innovation award at the upcoming Biotech Week Boston Awards! The Biotech Innovation award recognizes a company that has conceived a new or advancing biopharmaceutical product, manufacturing

Alltrna’s CEO Michelle Werner discusses with Rare Disease Advisor her personal and professional mission to accelerate #raredisease #drugdevelopment and how new tRNA genetic medicines could do this: by treating many diseases at once. 🎧 Listen to the interview:

What a great way to help nourish our community! A team of Alltrna volunteers helped out two fantastic local charities, Cradles to Crayons Massachusetts & Community Servings during our #DayofService. 📸 Check out these snapshots from the day. #WeAreAlltrna #EndClothingInsecurity #FoodHeals

🤔 Why should you get genetic testing if you already have a diagnosis? New animated videos from #NORD outline many of the reasons, such as determining the best treatment, expanding clinical trial options, and providing additional support. We are proud to have provided funding

Our CEO Michelle Werner will be speaking twice at #RNALeaders, taking place this week in #SanDiego. Thursday, September 5th 1:55 pm to 2:20 pm PT Talk – Leveraging Machine Learning to Design tRNA Medicines to Treat Stop Codon Disease 3:30 pm to 4:15 pm PT Closing Keynote

While families with #Duchenne muscular dystrophy have more hope than ever before, they are also feeling overwhelmed, anxious and confused. To mark #WorldDuchenneAwarenessDay, Alltrna CEO Michelle Werner shares the agonizing decision she faced on behalf of her teenage son, and

We are so excited to share that FierceHealthcare and Fierce Life Sciences have named Alltrna’s CEO Michelle C. Werner as one of 𝟮𝟬𝟮𝟰’𝘀 #𝗙𝗶𝗲𝗿𝗰𝗲𝟱𝟬 𝗵𝗼𝗻𝗼𝗿𝗲𝗲𝘀! It’s great to see the recognition for her patient advocacy and leadership at @Alltrna as we pioneer #tRNA